These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

328 related items for PubMed ID: 15200747

  • 1. Efficacy and tolerability of initial combination therapy with nateglinide and metformin in treatment-naïve patients with type 2 diabetes.
    Horton ES, Foley JE, Shen SG, Baron MA.
    Curr Med Res Opin; 2004 Jun; 20(6):883-9. PubMed ID: 15200747
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes.
    Horton ES, Clinkingbeard C, Gatlin M, Foley J, Mallows S, Shen S.
    Diabetes Care; 2000 Nov; 23(11):1660-5. PubMed ID: 11092289
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin.
    Raskin P, Klaff L, McGill J, South SA, Hollander P, Khutoryansky N, Hale PM, Repaglinide vs. Nateglinide Metformin Combination Study Group.
    Diabetes Care; 2003 Jul; 26(7):2063-8. PubMed ID: 12832314
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. PRESERVE-beta: two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin.
    Gerich J, Raskin P, Jean-Louis L, Purkayastha D, Baron MA.
    Diabetes Care; 2005 Sep; 28(9):2093-9. PubMed ID: 16123472
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P, Sitagliptin Study 035 Group.
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin.
    Barnett AH, Charbonnel B, Donovan M, Fleming D, Chen R.
    Curr Med Res Opin; 2012 Apr; 28(4):513-23. PubMed ID: 22313154
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Efficacy, tolerability and safety of nateglinide in combination with metformin. Results from a study under general practice conditions.
    Schatz H, Schoppel K, Lehwalder D, Schandry R.
    Exp Clin Endocrinol Diabetes; 2003 Aug; 111(5):262-6. PubMed ID: 12951631
    [Abstract] [Full Text] [Related]

  • 16. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.
    Hemmingsen B, Sonne DP, Metzendorf MI, Richter B.
    Cochrane Database Syst Rev; 2016 Oct 17; 10(10):CD012151. PubMed ID: 27749986
    [Abstract] [Full Text] [Related]

  • 17. Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus.
    Bosi E, Dotta F, Jia Y, Goodman M.
    Diabetes Obes Metab; 2009 May 17; 11(5):506-15. PubMed ID: 19320662
    [Abstract] [Full Text] [Related]

  • 18. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy.
    Ferrannini E, Fonseca V, Zinman B, Matthews D, Ahrén B, Byiers S, Shao Q, Dejager S.
    Diabetes Obes Metab; 2009 Feb 17; 11(2):157-66. PubMed ID: 19125777
    [Abstract] [Full Text] [Related]

  • 19. Repaglinide versus nateglinide monotherapy: a randomized, multicenter study.
    Rosenstock J, Hassman DR, Madder RD, Brazinsky SA, Farrell J, Khutoryansky N, Hale PM, Repaglinide Versus Nateglinide Comparison Study Group.
    Diabetes Care; 2004 Jun 17; 27(6):1265-70. PubMed ID: 15161773
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.